Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT03860233
PHASE1

Benefits of Oxytocin in Obstructive Sleep Apnea (OSA) Patients Using Continuous Positive Airway Pressure (CPAP) Machine

Sponsor: Vivek Jain

View on ClinicalTrials.gov

Summary

This study will investigate if an intra-nasal nose spray of the drug oxytocin can decrease the amount of pressure needed from the automatic Continuous Positive Airway Pressure (CPAP) device while sleeping decreasing some of the harmful effects of low oxygen in people with sleep apnea. This study will last 35 nights and involves spending three nights in the sleep lab at George Washington University. There are no additional costs to participants and no compensation for being involved in the study.

Official title: Benefits of Oxytocin in OSA Patients Using CPAP

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2019-03-04

Completion Date

2026-03-01

Last Updated

2025-03-21

Healthy Volunteers

No

Interventions

DRUG

Oxytocin

40 IU administered intranasal, within 1 hour prior to sleeping for 14 days

DRUG

Placebo

Intranasal spray to mimic Oxytocin intranasal spray

Locations (1)

Medical Faculty Associates

Washington D.C., District of Columbia, United States